礼来公司 （Eli Lilly） 超出了盈利预期，上调了 2025 年的指引，并在强劲的销售和内部购买中提高了股息。 Eli Lilly beat earnings estimates, raised 2025 guidance, and boosted dividends amid strong sales and insider buying.

Eli Lilly和Company报告,Q2收入丰厚,Eli Lilly和Company的E2收入为6.31 EPS,超过估计数72美元,收入15.56亿美元,比同年增长37.6%。 Eli Lilly and Company reported strong Q2 earnings with $6.31 EPS, surpassing estimates by $0.72, and $15.56 billion in revenue, up 37.6% year-over-year. 该公司的股票有内幕购买,包括从CEO David Ricks和董事Sulzberger和Fyrwald购买,而像财富增强咨询服务这样的机构投资者则增加了持有量。 The company’s stock saw insider purchases, including from CEO David Ricks and Directors Sulzberger and Fyrwald, while institutional investors like Wealth Enhancement Advisory Services increased holdings. 尽管JP摩根公司和UBS公司的一些价格目标降级,但股票仍保持“多价购买”共识评级和939.61美元平均价格目标。 Despite some price target downgrades from JPMorgan and UBS, the stock maintains a "Moderate Buy" consensus rating and a $939.61 average price target. Eli Lilly的市场上限为7 220亿美元,继续在糖尿病和肥胖症治疗中居领先地位,最近宣布季度红利为1.50美元,并提升了2025年EPS指南。 Eli Lilly, with a $722 billion market cap, continues to lead in diabetes and obesity treatments, recently announced a $1.50 quarterly dividend, and raised its 2025 EPS guidance.